Nathan Warner
Psychiatric/Mental Health · Houston, MONPI 1659589133
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 535 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$998
- Lundbeck LLC$490
- Supernus Pharmaceuticals, Inc.$437
- Axsome Therapeutics, Inc.$419
- plus $4K from 24 others
What the payments were for
- Food & beverage$9,37199%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 136 | $2,226 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $1,363 |
| Otsuka America Pharmaceutical, Inc. | 58 | $998 |
| Lundbeck LLC | 35 | $490 |
| Supernus Pharmaceuticals, Inc. | 16 | $437 |
| Axsome Therapeutics, Inc. | 19 | $419 |
| Neurocrine Biosciences, Inc. | 24 | $386 |
| Alkermes, Inc. | 16 | $382 |
| Johnson & Johnson | 29 | $378 |
| Harmony Biosciences LLC | 22 | $364 |
| Teva Pharmaceuticals USA, Inc. | 14 | $249 |
| Jazz Pharmaceuticals Inc. | 11 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $210 |
| E.r. Squibb & Sons, L.L.C. | 17 | $203 |
| Indivior Inc. | 9 | $167 |
| Tris Pharma Inc | 7 | $138 |
| Bausch Health US, LLC | 6 | $126 |
| Vanda Pharmaceuticals Inc. | 6 | $126 |
| Sunovion Pharmaceuticals Inc. | 10 | $104 |
| Idorsia Pharmaceuticals US Inc | 5 | $88 |
| Corium, LLC | 5 | $78 |
| Avanir Pharmaceuticals, Inc. | 3 | $46 |
| Merck | 3 | $44 |
| Ironshore Pharmaceuticals Inc. | 2 | $43 |
| Noven Therapeutics, LLC | 2 | $41 |
| Biogen | 2 | $39 |
| Neos Therapeutics, LP | 2 | $37 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Noven Pharmaceuticals, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,476 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 29 | $231,388 |
| Invega SustennaPaliperidone Palmitate | 49 | $171,858 |
| RexultiBrexpiprazole | 60 | $88,168 |
| SpravatoEsketamine Hcl | 24 | $46,128 |
| VraylarCariprazine Hcl | 32 | $45,552 |
| CaplytaLumateperone Tosylate | 23 | $40,922 |
| Abilify MaintenaAripiprazole | 12 | $33,618 |
| Aripiprazole | 191 | $15,685 |
| VyvanseLisdexamfetamine Dimesylate | 41 | $15,470 |
| TrintellixVortioxetine Hydrobromide | 17 | $12,512 |
| Divalproex Sodium ErDivalproex Sodium | 98 | $9,029 |
| Olanzapine | 186 | $8,061 |
| Clozapine | 80 | $7,082 |
| Paliperidone ErPaliperidone | 45 | $6,366 |
| Vilazodone Hcl | 46 | $6,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $386 | $231,38829 claims |
| Johnson & JohnsonInvega Sustenna, Spravato | $378 | $217,98673 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $998 | $121,78672 claims |
| AbbVieVraylar | $2,226 | $45,55232 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,363 | $40,92223 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $210 | $27,98358 claims |
| MerckBelsomra | $44 | $5,76313 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $437 | $4,06612 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $1,578148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Houston
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
- Kelsey KingsboroughMexico$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.